Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 6/20 | 1.00 |
| ▸ | CCNH | P51946 | 6/20 | 1.00 |
| ▸ | MNAT1 | P51948 | 6/20 | 1.00 |
| ▸ | PAK4 | O96013 | 14/20 | 0.83 |
| ▸ | CDK2 | P24941 | 5/20 | 0.83 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.81 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.81 |
| ▸ | CDK9 | P50750 | 1/20 | 0.81 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.81 |
| ▸ | MELK | Q14680 | 1/20 | 0.69 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20741157 | 1.00 | CDK7 (1.00) | CDK7CCNHMNAT1PAK4CDK2 | |
| SCHEMBL17878656 | 0.92 | CDK7 (0.84) | CDK7CCNHMNAT1PAK4CDK2 | |
| SCHEMBL20741178 | 0.92 | CDK7 (0.84) | CDK7CCNHMNAT1PAK4CDK2 | |
| SCHEMBL1205139 | 0.91 | PAK4 (1.00) | CDK7CCNHMNAT1PAK4CDK2 | |
| SCHEMBL28720438 | 0.90 | PAK4 (0.92) | CDK7CCNHMNAT1PAK4CDK2 | |
| SCHEMBL28713458 | 0.90 | PAK4 (0.92) | CDK7CCNHMNAT1PAK4CDK2 | |
| SCHEMBL20741190 | 0.89 | CDK7 (1.00) | CDK7CCNHMNAT1PAK4CDK2 | |
| SCHEMBL17878720 | 0.89 | CDK7 (1.00) | CDK7CCNHMNAT1PAK4CDK2 | |
| SCHEMBL29507384 | 0.89 | PAK4 (0.89) | CDK7CCNHMNAT1PAK4CDK2 | |
| SCHEMBL1206517 | 0.89 | PAK4 (0.89) | CDK7CCNHMNAT1PAK4CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3236959-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA FARBER CANCER INST INC (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12168663-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20230000870-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-01-05 | — | — | US | disclosed |
| US-20220024929-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220024929-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| WO-2021087138-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| US-20210115051-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-20210115051-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-10870651-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-10870651-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190055248-A1 | INHIBITORS OF CYCLINDEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. | 2019-02-21 | — | — | US | disclosed |
| US-20190055248-A1 | INHIBITORS OF CYCLINDEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. | 2019-02-21 | — | — | US | disclosed |
| WO-2016105528-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168663-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 35/4885MNAT1 206/4885 |
| US-20220024929-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 35/4885MNAT1 206/4885 |
| US-20230000870-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, RB1, MKI67 | CDK7 1/4885CCNH 17/4885MNAT1 1007/4885 |
| US-20190055248-A1 | INHIBITORS OF CYCLINDEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 37/4885MNAT1 164/4885 |
| US-20210115051-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 35/4885MNAT1 206/4885 |
| US-10870651-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | CDK7 1/4885CCNH 35/4885MNAT1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.